HyBryte™

Rook, A.H., et al., A phase II placebo-controlled study of photodynamic therapy with topical hypericin and visible light irradiation in the treatment of cutaneous T-cell lymphoma and psoriasis. J Am Acad Dermatol, 2010. 63(6): p. 984-90.

Degar, S., et al., Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Res Hum Retroviruses, 1992. 8 (11): p. 1929-36.

Criscione, V.D. and M.A. Weinstock, Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol, 2007. 143(7): p. 854-9.

Blank, M., et al., Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. Cancer Res, 2003. 63(23): p.
8241-7.

Fox, F.E., et al., Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. J Invest Dermatol, 1998. 111(2): p. 327-32.

Lenard, J., A. Rabson, and R. Vanderoef, Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci U S A, 1993. 90(1): p. 158-62.

Meruelo, D., G. Lavie, and D. Lavie, Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci U S A, 1988. 85(14): p. 5230-4.

Duran, N. and P.S. Song, Hypericin and its photodynamic action. Photochem Photobiol, 1986. 43
(6): p. 677-80.